Alios BioPharma competitors

Jon P. Stonehouse, a pharmaceutical executive for more than 20 years, has strong commercialization, financial transaction, business development and management expertise. He most recently served as Senior Vice President of Corporate Development at Merck KGaA with responsibility for global licensing and business development, corporate mergers and acquisitions, corporate strategic planning and alliance management. Among his accomplishments, he was responsible for leading the effort to develop a strategy for Merck that significantly changed the company. This culminated with the acquisition of Serono, S.A., the largest biotechnology company in Europe at the time of the agreement.

Troy Wilson is a highly-successful, serial entrepreneur. His passion is to build exceptional companies that create significant value for employees, investors and most importantly, patients. In addition to his role as President and CEO of Avidity NanoMedicines, Troy Wilson is President and CEO of Wellspring Biosciences as well as its affiliated company, Araxes Pharma. He also serves as a director of Puma Biotechnology, a biopharmaceutical company dedicated to the acquisition and development of novel therapeutics for the treatment of cancer. Troy Wilson previously served as President and CEO of Intellikine, a company which he co-founded and which was acquired by Takeda Pharmaceuticals in January 2012 for up to $310 million, and prior to Intellikine he was involved with the formation, launch and growth of several other companies. Troy Wilson received his Ph.D. degree in bioorganic chemistry from the University of California, Berkeley and his law degree from New York University.

Maxwell Stock has the primary responsibility of spearheading Signum's business development efforts in combination with developing strategic plans to advance the company's mission and objectives. An inventor on Signum patents and a co-founder of the company, his extensive laboratory experience and familiarity with our science have been critical in executing and maintaining Signum's strategic partnerships. He majored in molecular biology at the University of Colorado, conducted research efforts at Synergen, Inc., and founded several startups before founding Signum and joining professor Stock's Princeton laboratory to develop the technologies upon which Signum is built.